2015 HRS Expert Consensus Statement on POTS, IST, and Vasovagal Syncope

Authors, Journal, Affiliations, Type, DOI

• Authors: Sheldon RS, Grubb BP II, Olshansky B, Shen W-K, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA, Moak JP, Sandhu RK, Kanjwal K
• Journal: Heart Rhythm, Vol 12, No 6, June 2015 (pp. e41–e63)
• Affiliations: Multi-institutional — Libin Cardiovascular Institute of Alberta; University of Toledo; Johns Hopkins University; Mayo Clinic; Vanderbilt University; Imperial College London; New York Medical College; McMaster University; Cleveland Clinic; Children's National Medical Center; and others
• Type: Expert consensus statement
• Endorsing societies: HRS, AAS, ACC, AHA, APHRS, EHRA, PACES, SOLAECE
• DOI: https://doi.org/10.1016/j.hrthm.2015.03.029

Overview

This international multi-society consensus establishes working diagnostic criteria and management recommendations for three overlapping autonomic disorders: postural tachycardia syndrome (POTS), inappropriate sinus tachycardia (IST), and vasovagal syncope (VVS). The document provides evidence-graded Class I–III recommendations across investigation and treatment for each syndrome, explicitly acknowledging that high-level RCT evidence is sparse for all three conditions. Recommendations are based on consensus vote (minimum 76%, mean 94% agreement). Numerous areas requiring future collaborative research are identified.

Keywords

Postural tachycardia syndrome, inappropriate sinus tachycardia, vasovagal syncope, orthostatic intolerance, autonomic neuropathy, tilt-table testing, ivabradine, midodrine, fludrocortisone, pacemaker, ISSUE-3

Key Takeaways

Section 1: Postural Tachycardia Syndrome (POTS)

Definition

POTS is defined by: (1) symptoms occurring with standing (lightheadedness, palpitations, tremor, weakness, blurred vision, exercise intolerance, fatigue); (2) HR increase ≥30 bpm on moving from recumbent to standing held >30 seconds (≥40 bpm in those aged 12–19 years); (3) absence of orthostatic hypotension (>20 mmHg drop in systolic BP). Standing HR is often ≥120 bpm. POTS and VVS diagnoses are not mutually exclusive.

Epidemiology and Natural History

• Prevalence approximately 0.2%; more than 75% female; peak onset age 15–25 years
• Also common in patients with chronic fatigue syndrome
• Perceived as a chronic condition with no known mortality and eventual improvement; course varies substantially between patients

Physiology — Four Overlapping Subtypes

• Peripheral autonomic denervation (neuropathic): Up to 50% of POTS patients have restricted autonomic neuropathy of distal postganglionic sudomotor fibers (predominantly feet and toes); impaired sympathetic tone reduces venoconstriction → venous pooling in lower limbs and splanchnic beds; compensatory high cardiac output required; may have autoimmune basis in some patients; associated with Ehlers-Danlos syndrome (abnormal connective tissue → excessive venous distension)
• Hypovolemia: Blood volume reduced in up to 70% of patients; paradoxically low renin/aldosterone with inappropriately elevated angiotensin II — "low-flow subtype"
• Hyperadrenergic POTS: Up to 50% of patients; systolic BP increase ≥10 mmHg standing + plasma norepinephrine ≥600 pg/mL; prominent sympathetic symptoms (palpitations, anxiety, tachycardia, tremor); hypersensitive to isoproterenol
• Deconditioning: Reduced LV mass, stroke volume, blood volume — all improve with exercise training; unclear if primary cause or secondary phenomenon
• Anxiety is commonly present but orthostatic tachycardia response is physiologic, not anxiety-driven (Masuki et al.)

Diagnosis

• All patients: complete history, orthostatic vital signs, 12-lead ECG
• Selected: thyroid function, hematocrit, 24h Holter, echocardiogram, exercise stress testing
• Tilt-table test if orthostatic vital signs normal but clinical suspicion high (captures prolonged vital sign changes beyond simple stand test)
• Extended evaluation (thermoregulatory sweat test, supine/upright catecholamines, 24h urine sodium, psychological assessment) only if symptoms fail to improve — not routine

Treatment

• Non-pharmacologic first (all patients): Withdraw aggravating medications (norepinephrine transport inhibitors); salt 10–12 g/day + fluid 2–3 L/day; compression garments; graduated supervised aerobic exercise beginning non-upright (rowing machine, recumbent bike, swimming) + thigh resistance training
• Pharmacologic:
  • Fludrocortisone: sodium retention/plasma volume expansion; pharmacodynamic effects may last only 1–2 days; not tested in RCTs for POTS
  • Midodrine: peripheral α-1 agonist; significantly reduces orthostatic tachycardia; 3× daily daytime only (supine hypertension risk)
  • IV saline (1L over 1h): anecdotal rescue for decompensated patients; not for routine use (central catheter complications with chronic use)
  • Low-dose propranolol (10–20 mg): acutely lowers standing HR and improves symptoms; long-acting formulation does NOT improve QoL; higher doses less tolerated
  • Ivabradine: If current blocker; ~60% symptom improvement in open-label study; no BP effect (was not US-approved at time of guideline)
  • Pyridostigmine: peripheral acetylcholinesterase inhibitor; blunts orthostatic tachycardia; limited by GI side effects
  • Clonidine/methyldopa (central sympatholytics): useful in hyperadrenergic POTS; cause drowsiness/fatigue; may worsen cognitive dysfunction
  • Modafinil: may help fatigue and brain fog but can worsen tachycardia
• Invasive — NOT recommended:
  • Radiofrequency sinus node modification: often worsens symptoms; risk of permanent pacemaker requirement
  • Chiari I decompression: no established association with POTS; not to be offered without prospective controlled data

Section 2: Inappropriate Sinus Tachycardia (IST)

Definition

IST: sinus heart rate >100 bpm at rest (mean 24-hour HR >90 bpm, not due to primary causes) associated with distressing palpitation symptoms.

Epidemiology and Natural History

• Prevalence approximately 1.2% (using Holter-based definition in a middle-aged population)
• No known mortality; believed to be chronic; natural history unclear

Physiology

Incompletely understood; mechanisms include: increased sinus node automaticity, β-adrenergic hypersensitivity (β-adrenergic receptor antibodies sensitising receptors in some patients), decreased parasympathetic activity, and impaired neurohumoral modulation. IST is triggered by physiologic AND emotional stresses — distinguishing feature from POTS (orthostatic stress only). IST is rarely associated with tachycardia-mediated cardiomyopathy.

Diagnosis

• History and physical to exclude primary sinus tachycardia causes (thyroid, medications, drugs, hypovolemia, POTS)
• 12-lead ECG to document sinus rhythm and exclude other atrial tachyarrhythmias
• 24h Holter to confirm mean HR >90 bpm criterion
• Cardiovascular autonomic reflex tests and treadmill testing not recommended routinely

Treatment

• No long-term placebo-controlled RCT evidence for any therapy
• Significant psychosocial distress requires close attention; effective communication can improve outcomes
• Ivabradine (most evidence-based): Blocks If current; 5–7.5 mg BID; slows HR 25–40 bpm; eliminated symptoms in 70% of patients in a small crossover RCT (n=21, 12 weeks); combination with metoprolol may be safe and effective
• Beta-blockers: Not usually effective; cause adverse effects
• Other suggested treatments with limited evidence: fludrocortisone, volume expansion, compression stockings, phenobarbital, clonidine, psychiatric evaluation, exercise training, erythropoietin
• Sinus node modification/ablation: Not recommended for routine care; good initial success but high symptom recurrence; significant complications (permanent pacemaker requirement, phrenic nerve paralysis [transient or permanent], transient SVC syndrome); may be offered in highly selected circumstances or research protocols only

Section 3: Vasovagal Syncope (VVS)

Definition

• Syncope: Transient loss of consciousness with inability to maintain postural tone, rapid and spontaneous recovery, no features specific to another cause (e.g., seizure)
• VVS: Syncope syndrome with (1) upright posture >30 seconds OR emotional stress/pain/medical setting; (2) diaphoresis, warmth, nausea, pallor; (3) hypotension and relative bradycardia; (4) fatigue on recovery

Epidemiology and Natural History

• Cumulative incidence by age 60: 42% women, 32% men (actuarial methodology)
• Incidence increases markedly around age 11; median first syncope age ~14 years; most first episodes before age 40
• Manifested as pallid syncope in ~1–3% of toddlers
• ~30–50% of syncope in emergency department settings is autonomically mediated, most vasovagal
• Outcome generally benign — no increased mortality; 1-year recurrence rate ~25–35%
• 1-year recurrence predicted by prior-year syncope burden: 7% if no syncope in past year vs 40% if ≥1 episode (POST study)

Physiology

• Upright position → gravitational pooling 500–800 mL blood (venous/pelvic/splanchnic/lower limbs) → reduced venous return → decreased cardiac output and BP → baroreceptor-triggered sympathetic noradrenergic vasoconstriction and HR increase
• During VVS episode: ineffective reflex → venous pooling → paradoxical vasodilation → hypotension + vagal cardioinhibition (relative or absolute bradycardia, sometimes prolonged asystole in sinus and AV nodes)
• Initial BP reduction driven primarily by 50% decline in cardiac output; vasodilatation occurs in only a subset of patients
• MSNA persistence during VVS recently reported by 2 independent groups — challenges classical sympathetic withdrawal model
• Two physiologic phenotypes (by supine BP):
  • Low-pressure (SBP <100 mmHg): low tyrosine hydroxylase → reduced NE synthesis
  • Normal-pressure (SBP >100 mmHg): increased norepinephrine transporter → augmented NE reuptake
  • Both phenotypes have reduced NE availability → impaired neurocirculatory response to orthostatic stress

Diagnosis

• Based on clinical history: predisposing situation (prolonged standing ≥2–3 minutes; emotional/pain/medical context), prodrome (diaphoresis, warmth, flushing, nausea, visual blurring), recovery features (fatigue for minutes to hours), unconsciousness usually <1–2 minutes
• Fine/coarse myoclonic movements observed in ~10% — can mimic epilepsy; videometric analysis and home videos helpful
• Diagnostic scores available (high accuracy) but require further validation
• Tilt-table testing:
  • Sensitivity 78–92% in high-pretest probability populations; specificity ~90%
  • Positive response = clinically reminiscent presyncope/syncope with hypotension ± bradycardia
  • Does NOT establish causation — indicates predisposition/substrate
  • Most useful for: differentiating convulsive syncope from seizure; unclear diagnosis after careful history; establishing pseudosyncope
  • ISSUE-3 subanalysis: positive tilt test predicts patients who will NOT benefit from cardiac pacing
• Implantable loop recorder (ILR):
  • Gold standard for documenting rhythm during spontaneous syncope
  • Diagnostic yield ~35% over device lifetime
  • RCTs consistently show early ILR use improves diagnosis and care in older patients (predominantly 70s–80s study populations)
  • ILR benefit for directing pacing therapy best established in older patients with asystole + negative tilt test

Conservative and Medical Treatment

• Patients with occasional syncope: Reassure, salt/fluid intake, counterpressure maneuvers; do NOT treat if no syncope in past year
• Patients with recurrent syncope: Begin conservatively; review and withdraw hypotension-causing medications if possible
• Physical counterpressure maneuvers: Isometric exercise of large muscles during impending syncope prodrome; 39% relative risk reduction vs controls in prospective RCT; risk-free; recommended core management for all severity levels
• Tilt training: Home standing protocols not beneficial; clinic-based monitored protocols possibly beneficial but poor compliance and no definitive recommendation
• Beta-blockers: Adequately powered RCTs (POST I with metoprolol; atenolol RCT) show NOT effective overall; signal of benefit in patients >40 years from POST meta-analysis; reasonable to use metoprolol in older patients, avoid in younger
• Fludrocortisone: POST 2 showed strong trend to benefit only (unpublished at time of guideline); pediatric trial showed placebo superior; reasonable to try in severe cases
• Midodrine: ~70% risk reduction across 4 RCTs; all with design limitations (pediatric populations, tilt test outcomes, open-label, or extraordinarily symptomatic patients); caution: supine hypertension, urinary retention in older men, unknown teratogenic effects; POST 4 (conventional placebo-controlled RCT) was ongoing
• Serotonin transporter inhibitors: Biologically plausible; limited evidence from 3 small RCTs; considerable uncertainty about efficacy

Pacemaker Treatment

• Very limited role in typical VVS
• Earlier open-label and single-blind trials uniformly positive; 2 subsequent double-blind adult trials NEGATIVE
• No positive placebo-controlled pacemaker trial in patients <40 years — pacing should be last resort in this age group
• ISSUE-3 (n=511, age ≥40, recurrent reflex syncope; ILR-based selection):
  • Only 17% had qualifying asystole (≥6 seconds asystole without syncope, or any asystole during syncope)
  • Dual-chamber pacing with rate-drop response vs sensing-only (double-blind)
  • 2-year syncope recurrence: 25% pacemaker ON vs 57% pacemaker OFF — 57% relative risk reduction
  • Critical subanalysis: Asystole + negative tilt test → 5% recurrence with pacing; asystole + positive tilt test → 55% recurrence (similar to controls without pacing)
  • Positive tilt test identifies patients who should NOT undergo permanent cardiac pacing
• Adenosine-mediated unexplained syncope: Distinct entity — low plasma adenosine; no prodrome; normal heart/ECG; paroxysmal AV block without preceding sinus/AV node changes; pacing effectively prevents recurrence
• Pacing candidate criteria: Age significantly >40 years + frequent recurrences + repeated injury + limited prodrome + documented asystole on ILR + NEGATIVE tilt test
• Pacing mode: dual-chamber with rate-drop response used in trials; no comparisons with single-chamber pacing conducted

Section 4: Pediatric Considerations

• POTS diagnostic threshold in young: HR increase ≥40 bpm (vs ≥30 in adults); 10-minute standing test not validated for pediatric populations
• ECG recommended for all pediatric syncope to screen for dangerous arrhythmic causes
• Syncope during exercise in pediatrics: most common cause still VVS, but assess for cardiomyopathy and arrhythmia
• Pseudosyncope should be suspected when syncope is very frequent (daily) or prolonged
• Treatment: reassurance, salt/fluid, counterpressure techniques; midodrine effective (2 pediatric RCTs); fludrocortisone and metoprolol no better than placebo in children
• Pacing only in very young patients with frequent VVS + documented asystole refractory to multiple medications (1 small single-blind RCT)

Limitations of the document

• 2015 publication — ivabradine was not US-approved at time of writing (FDA approval obtained subsequently)
• Very limited high-level RCT evidence across all three conditions; most pharmacologic recommendations based on small, open-label, or uncontrolled trials
• POST 2 (fludrocortisone in VVS) and POST 4 (midodrine in VVS) results were not yet published at time of guideline
• Pediatric sections largely extrapolated from adult data
• Wide heterogeneity in reporting sites and patient populations limits generalizability
• POTS physiology heterogeneous — unclear whether it is one syndrome or multiple related syndromes
• Regulatory fragmentation across countries impedes multicenter trial conduct

Key Concepts Mentioned

• concepts/POTS — diagnostic criteria, 4 subtypes, treatment hierarchy
• concepts/Inappropriate-Sinus-Tachycardia — diagnostic criteria, ivabradine evidence
• concepts/Vasovagal-Syncope — diagnostic approach, ISSUE-3 pacing data, two physiologic phenotypes

Key Entities Mentioned

• Ivabradine — If current blocker; most evidence-based drug for both POTS and IST
• Midodrine — Peripheral α-1 agonist; used in POTS and VVS
• Fludrocortisone — Mineralocorticoid; plasma volume expansion in POTS and VVS
• ISSUE-3 — Landmark RCT defining pacing indication in VVS with documented asystole

Wiki Pages Updated

• Created wiki/sources/POTS-IST-VVS-HRS-2015.md
• Created wiki/concepts/POTS.md
• Created wiki/concepts/Inappropriate-Sinus-Tachycardia.md
• Created wiki/concepts/Vasovagal-Syncope.md
• Updated wiki/sourceindex.md
• Updated wiki/wikiindex.md
• Appended log.md